Niaid dmid influenza vaccine project (H5N1) - influenza variant virus vaccines
Active Awarded
- Contract number
- 75N91024F00032
- Awardee
-
Leidos Biomedical Research Inc. UEI HV8BH9BPG8Y9 Part of Leidos Holdings, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $7,985,002
Award facts
- Contract value 41% obligated
-
- $7,985,002.00 Current, with exercised options
- $19,476,349.00 Potential, with all options
- Completion date 71% complete
- Current and potential, with all options
- Funding agency
- National Institute of Allergy and Infectious Diseases National Institutes of Health, Department of Health and Human Services
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21702, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
About this award
This is a federal contract award from the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), to Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc. The contract is for the NIAID Division of Microbiology and Infectious Diseases (DMID) Influenza Vaccine Project (H5N1) to develop influenza variant virus vaccines. The contract has a ceiling value of $19,476,349.00 and is a Delivery Order with a Cost Plus Fixed Fee pricing type. The contract does not have a set-aside designation. Leidos Biomedical Research Inc. is an FFRDC contractor for the National Cancer Institute (NCI) and has supported various research efforts across disease areas like influenza, COVID-19, and gene therapy. The work will be primarily performed at Leidos Biomedical Research facilities in Fort Detrick and Frederick, Maryland.
Quick answers
Who was awarded contract 75N91024F00032?
75N91024F00032 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on September 9, 2024.
How much is contract 75N91024F00032 worth?
The government has obligated $7,985,002 on 75N91024F00032. Its potential value, with all options, is $19,476,349.
Which agency awarded contract 75N91024F00032?
National Cancer Institute (National Institutes of Health) awarded 75N91024F00032, with funding from National Institute of Allergy and Infectious Diseases (National Institutes of Health).
Is contract 75N91024F00032 an order under another contract?
Yes. 75N91024F00032 is a delivery order under 75N91019D00024, an indefinite delivery contract.
Was contract 75N91024F00032 competed?
The extent of competition for 75N91024F00032 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award